The investigation into the heparin incident in the United States was similar to the results of the food and drug administration (FDA). In February 2008

　　In the middle and early part of this year, four U.S. patients died after taking the anticoagulant Heparin from Baxter, and more than 300 others developed allergic reactions and other side effects. The underlying cause of death and allergic events is not yet known. The us food and drug administration (FDA) said on February 14, 2008 that it had not yet conducted an investigation into Chinese suppliers of the active ingredient in heparin, but planned to do so as soon as possible. Since then, it has been reported that the us side has sent an investigation team to China to investigate relevant issues.

　　Heparin sodium is the earliest anticoagulant developed and has the largest clinical dosage. It has been on the market for more than half a century. China is the world's second largest pig breeding country after the United States. It is rich in raw materials of heparin sodium and has become the world's second largest producer of heparin sodium after Europe.

　　On February 19, 2008, at the regular press conference of the Chinese foreign ministry, a reporter mentioned that the us had found a suspected problem with some Chinese drugs. Liu jianchao, spokesman of the Chinese foreign ministry, said, "the us raised relevant issues with the Chinese side, and the Chinese side immediately conducted an investigation."